Adipotide (FTPP): A Proapoptotic Peptide Targeting Adipose Vasculature

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to adipotide (FTPP). Adipotide is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

A peptide that selectively destroys the blood vessels feeding fat tissue sounds, at first encounter, like a mechanism too precise to be real. The preclinical research behind adipotide suggests the biology is genuine. The clinical development record tells a more complicated story.

This article covers what adipotide is, how its homing-peptide-plus-proapoptotic-peptide architecture works, what the landmark primate study found, the kidney toxicity signal that stopped its clinical trajectory, and where the science currently stands.

Key Takeaways

• Regulatory Status: Not FDA-approved for human use. Adipotide has no approved indication, no compounding classification, and no legal pathway for human use in the United States. As of April 2026, it is not on the FDA's 503A compoundable substances list.
• Research Stage: Extensive preclinical literature and one primate study; no completed, published human efficacy trials as of April 2026. A company-sponsored Phase 1 oncology trial was announced in 2012 but produced no peer-reviewed published results.
• Availability: Not legally marketed for human use. Superpower does not offer this substance.
• What it is: A peptidomimetic composed of a white-adipose-tissue-homing sequence fused to a mitochondria-disrupting proapoptotic domain, studied for targeted fat-cell death via vascular ablation.
• What the evidence actually shows: Robust preclinical weight loss in rodent and primate models, accompanied by a dose-dependent kidney toxicity signal that has not been characterized in humans. PubChem CID 163360068.

Where Adipotide Comes From and How It Works

Origin and discovery

Adipotide originated in the laboratory of Renata Pasqualini and Wadih Arap at the M.D. Anderson Cancer Center. The foundational work was published in Nature Medicine in 2004 by Kolonin, Saha, Chan, Pasqualini, and Arap, who used phage-display technology to screen for peptide sequences that home selectively to the blood vessels supplying white adipose tissue in obese mice. The approach builds on an earlier 1999 proof-of-concept by Ellerby, Arap, Ellerby, and colleagues, also in Nature Medicine, which demonstrated that a vascular-homing peptide could be coupled to a proapoptotic effector domain to kill targeted endothelial cells. Adipotide is the direct application of that architecture to the vasculature of fat tissue. The broader phage-display methodology that underpinned the discovery was formalized in a 2002 Nature Medicine paper by Arap, Kolonin, Trepel, and colleagues that laid out the platform for mapping the human vasculature by peptide homing.

The homing-peptide and proapoptotic-peptide fusion

Adipotide is a bipartite molecule. The first segment, the nine-amino-acid sequence CKGGRAKDC, serves as the targeting module. In the 2004 paper by Kolonin and colleagues, phage-display screening identified this motif as one that homes selectively to the inner surface of blood vessels feeding white adipose tissue. The molecular receptor is prohibitin, a protein enriched on the luminal endothelium of adipose vasculature. Subsequent work from Salameh, Daquinag, Staquicini, and colleagues in JCI Insight in 2016, extended in a 2022 Diabetes paper by Gao, Daquinag, Yu, and Kolonin, showed that endothelial prohibitin-1 mediates bidirectional long-chain fatty acid transport in white and brown adipose tissue and that its loss in endothelial cells suppresses glucose utilization under high-fat-diet conditions — which helps explain why prohibitin expression is concentrated in these depots and why it represents a tractable molecular address. The second segment, D(KLAKLAK)₂, is a proapoptotic effector: when delivered into a cell, this sequence disrupts mitochondrial membranes and triggers apoptosis through cytochrome c release, a mechanism characterized by Mai, Mi, Kim, Ng, and Robbins in Cancer Research in 2001, who showed that fusing a protein transduction domain to (KLAKLAK)₂ triggered rapid apoptosis across tumor cell lines and, on direct intratumoral injection in C57BL/6 mice, shrank established MCA205 fibrosarcomas via mitochondrial membrane disruption and cytochrome c release. The two segments are joined by a short glycine linker. Once the CKGGRAKDC domain binds prohibitin on adipose endothelium, the D(KLAKLAK)₂ payload is internalized, the target cell undergoes apoptosis, and the blood vessels feeding that adipose depot are progressively ablated. Fat cells deprived of vascular supply then undergo secondary cell death.

Prohibitin as the adipose vascular address

The selectivity of adipotide depends on prohibitin's expression pattern. A 2013 review by Thuaud, Ribeiro, Nebigil, and Désaubry in Chemistry and Biology placed prohibitin in a broader context as a multifunctional scaffold protein implicated in mitochondrial integrity, cell signaling, and transcriptional regulation. A 2006 review by Mishra, Murphy L.C., and Murphy L.J. in the Journal of Cellular and Molecular Medicine established prohibitin's emerging roles in proliferation, apoptosis, and mitochondrial function. For adipotide's mechanism, what matters is the finding that prohibitin is specifically enriched at the vascular endothelium of white adipose tissue in obese animals, which gives the homing peptide its practical selectivity. Because the targeting relies on a receptor whose surface expression is tied to the metabolic state of the tissue, the biology is more nuanced than a purely anatomical address.

What the Research Shows

The foundational mouse study

In the 2004 Nature Medicine paper by Kolonin, Saha, Chan, Pasqualini, and Arap, the investigators treated diet-induced obese mice with the CKGGRAKDC-GG-D(KLAKLAK)₂ peptidomimetic and observed approximately 30% body weight reduction over 28 days of treatment. The reduction was attributed to apoptosis of adipose vascular endothelium and subsequent fat-cell resorption, not to changes in food intake per se. A follow-on study published in Diabetes in 2010 by Kim, Woods, Seeley, and colleagues treated diet-induced obese C57BL/6 mice (n = 8 per group) with the CKGGRAKDC-GG-D(KLAKLAK)₂ proapoptotic peptide at 150 μg subcutaneously over 27 days and reported significantly decreased cumulative energy intake and body weight in high-fat-diet-fed animals relative to vehicle controls (p < 0.05), with body weight of treated animals becoming statistically indistinguishable from lean low-fat-diet controls by day 27. Notably, the same dose did not produce a conditioned taste aversion, indicating that reduced intake was not simply an illness-like aversive response; the rodent-only design and small cohort limit any inference to humans. The same group, Kim, Woods, and Seeley, reporting in Diabetes in 2012 (n = 8 per group), found that the same proapoptotic peptide produced rapid improvement in glucose tolerance in obese C57BL/6 mice by days 2–3 of treatment in a weight- and food-intake-independent manner (p < 0.05), alongside significantly reduced serum insulin and triglycerides (both p < 0.05) — a finding that distinguishes the metabolic effects of the compound from simple fat loss and raises independent questions about how vascular disruption in adipose tissue affects systemic insulin signaling. Both studies were conducted in mice only; no human data were generated.

The rhesus monkey study

The most consequential study of adipotide in a non-human primate model was published in Science Translational Medicine in 2011 by Barnhart, Christianson, Hanley, and colleagues. The study enrolled spontaneously obese rhesus macaques (n = 10 treated, n = 5 controls) — a model that more closely approximates human obesity physiology than standard rodent models — and administered adipotide at 0.43 mg/kg subcutaneously daily for 28 days, followed by a 28-day recovery period. Treated primates lost approximately 10.6% of their body weight, with reductions in BMI and abdominal circumference and imaging-confirmed decreases in body fat (p < 0.0001), while untreated controls showed no change. Insulin resistance, assessed by fasting glucose and insulin measures, also improved in treated animals (p = 0.019). Importantly, the same paper described mild, dose-dependent, reversible renal tubular degeneration and regeneration accompanied by elevated serum creatinine that normalized post-treatment — a signal that would shape the compound's subsequent development trajectory as discussed below. The small cohort and short duration limit the strength of inferences that can be drawn about chronic-dosing safety.

Nanoparticle delivery and translational extensions

Follow-on work by Hossen, Kajimoto, Akita, Hyodo, and Harashima — published in the Journal of Controlled Release in 2012 and extended in the same journal in 2013 — explored whether nanoparticle delivery of the D(KLAKLAK)₂ payload targeting CKGGRAKDC-bound endothelium could achieve comparable efficacy with a different toxicity profile. These studies are notable primarily as engineering responses to the kidney toxicity signal identified in the primate study: if the delivery vehicle could be modified, the therapeutic window might be shifted. A 2013 paper by Azhdarinia, Daquinag, Tseng, and colleagues in Nature Communications adapted the same phage-display platform to identify a distinct brown-adipose-homing sequence (CPATAERPC) that selectively binds brown adipose vascular endothelium, using CKGGRAKDC as a white-fat control — work that validated the broader vascular-address strategy across adipose depots. Daquinag, Tseng, Zhang, and colleagues published in Molecular Therapy in 2016 on using hunter-killer peptides to deplete adipose stromal cells and suppress tumor growth in mouse models, a translational extension of the adipotide concept into oncology. An earlier 2015 paper in Cell Death and Differentiation by Daquinag, Tseng, Salameh, and colleagues demonstrated that depleting white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity in mice, establishing an adjacent targeting strategy from the same research lineage. The tumor-and-fat connection was further developed in a 2009 Cancer Research paper by Zhang, Daquinag, Traktuev, and colleagues showing that white adipose tissue cells are recruited by experimental tumors — context that supports the rationale for extending adipotide-type platforms into oncology and cachexia.

The conceptual precursor: anti-angiogenic weight loss

Adipotide's design was informed by an earlier conceptual demonstration. Rupnick, Panigrahy, Zhang, and colleagues published in PNAS in 2002 that anti-angiogenic agents including angiostatin and endostatin produced dose-dependent, reversible weight loss in ob/ob and diet-induced obese mice through vascular remodeling — decreased endothelial proliferation and increased apoptosis in adipose tissue. Pasarica, Sereda, Redman, and colleagues confirmed in Diabetes in 2009 that obese white adipose tissue is hypoxic and highly vascular-dependent. Together these findings established that the adipose vasculature is a legitimate pharmacological target and provided the intellectual context in which the Pasqualini–Arap group developed a receptor-targeted approach. The broader vascular-targeting anti-obesity strategy was subsequently reviewed by Daquinag, Zhang, and Kolonin in Trends in Pharmacological Sciences in 2011, which situates adipotide within the wider concept of ablating adipose vasculature as a therapeutic approach and discusses what would be required to translate the preclinical findings into clinical medicine.

Mechanistic confirmation of the KLAKLAK payload

Independent work has validated the mitochondrial mechanism of the D(KLAKLAK)₂ domain outside the adipose context. A 2021 paper by Bahmani, Sharifzadeh, and colleagues in the Journal of Biomedical Physics and Engineering reported that a mitochondria-targeted D(KLAKLAK)₂ peptide combined with gamma irradiation reduced cell viability and enhanced apoptosis in radio-resistant THP-1 human monocytic leukemia cells in vitro, and a 2013 PLoS One paper by Barbu, Shirazi, McGrath, and colleagues showed that a KLAKLAK-class antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis. These reports corroborate the proposed mechanism: the D(KLAKLAK)₂ sequence disrupts mitochondrial membranes in any cell type that internalizes it at sufficient concentration, which is why the selectivity of the upstream homing peptide matters so much for safety.

The Kidney Toxicity Signal and Why Clinical Development Stalled

What the primate study found

The Barnhart 2011 study reported dose-dependent changes to renal tubular morphology in adipotide-treated rhesus macaques. The histological findings were described as reversible upon cessation of treatment, meaning the kidney changes observed did not persist indefinitely after the compound was stopped. However, reversibility in a 28-day primate study does not characterize the full renal safety profile under chronic dosing conditions, at higher doses, or in humans. The kidney is the primary concern because the CKGGRAKDC peptide, once cleared from adipose binding sites, is processed renally, and the D(KLAKLAK)₂ domain's mitochondria-disrupting activity is not inherently selective for adipose tissue if delivered at sufficient concentration to renal tubular cells.

What no published human data means in practice

As of April 2026, no completed peer-reviewed human efficacy or safety trial of adipotide has been published. A Phase 1 oncology trial in prostate cancer patients with obesity, announced by Arrowhead Research Corporation (then Ablaris Therapeutics) around 2012, was registered with ClinicalTrials.gov. That trial produced no peer-reviewed published results. The absence of published human data is itself informative: it means there is no characterized human renal toxicity threshold, no established tolerated dose range, no human pharmacokinetic profile, and no long-term safety signal in any human population. The preclinical data, though promising in its mechanistic specificity, cannot substitute for human Phase 1 safety data. Adipotide's safety in humans remains entirely uncharacterized.

Adipotide vs. GLP-1 Receptor Agonists: A Mechanistic Distinction

Adipotide is mechanistically unrelated to GLP-1 receptor agonists such as semaglutide and tirzepatide, and that distinction matters for understanding where each sits in the research landscape. GLP-1 receptor agonists work through incretin signaling: they bind receptors in the gut and brain that regulate appetite, gastric emptying, and glucose metabolism, producing weight loss primarily by reducing caloric intake and improving insulin dynamics. The pivotal STEP 1 semaglutide trial, published in the New England Journal of Medicine in 2021 by Wilding, Batterham, Calanna, and colleagues, randomized 1,961 adults with overweight or obesity in a 2:1 ratio to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks and reported a mean body-weight change of −14.9% vs. −2.4% (treatment difference −12.4 percentage points; 95% CI, −13.4 to −11.5; p < 0.001), with nausea and diarrhea as the most common adverse events and treatment discontinuation for gastrointestinal events in 4.5% of the semaglutide group vs. 0.8% of placebo. Tirzepatide, as a dual GIP/GLP-1 receptor agonist, was characterized by Willard, Douros, Gabe, and colleagues in JCI Insight in 2020 as acting through imbalanced receptor engagement that produces additive metabolic effects. A 2021 review by Tak and Lee in Current Obesity Reports situates both agents in a class of hormonal-signaling-based weight-loss pharmacotherapies, reporting placebo-subtracted 12-month weight reductions of 2.9% to 6.8% across FDA-approved agents in the broader anti-obesity category.

Adipotide's mechanism is entirely separate: it targets the structural vasculature of fat tissue, not appetite-regulating hormones or receptors. This means the two approaches address obesity biology at different levels and with different risk profiles. GLP-1 receptor agonists have cleared Phase 3 trials and are FDA-approved for specific indications. Adipotide has not. This comparison is offered for scientific context only; the compounds have fundamentally different regulatory statuses and evidence bases.

Regulatory and Legal Status

FDA classification

As of April 2026, adipotide is not FDA-approved for any indication. It has no FDA drug application on file, no approved label, and no classification as a compoundable bulk drug substance under 503A or 503B. The FDA's list of bulk drug substances that may present significant safety risks specifies certain compounds by name; adipotide is not on the list of approved compoundable substances. There is no legal compounding pathway for adipotide in the United States.

What this means practically

Products labeled as adipotide or FTPP sold through online vendors exist outside any regulatory framework. There is no FDA oversight of manufacturing, no verified identity of the compound, no guaranteed purity or potency, and no established safe dose for human use. Independent testing of research-peptide products sold online has consistently found contamination, incorrect concentrations, and misidentified compounds. The kidney toxicity signal identified in primate research adds a specific mechanistic reason for concern: obtaining a misdosed or contaminated product that carries D(KLAKLAK)₂ activity is not a trivial risk. There is no legal pathway to obtain pharmaceutical-grade adipotide for human use in the United States, and no provider can legally prescribe it.

Safety: What Is and Is Not Known

Absence of human safety data

No peer-reviewed Phase 1 human safety data for adipotide exists. The standard information that characterizes a compound's human safety profile — including maximum tolerated dose, pharmacokinetics, dose-limiting toxicities, and organ-specific effects at clinically relevant exposures — is entirely absent for adipotide. The renal tubular changes observed in primates at doses that produced meaningful fat loss represent the primary known safety signal, but whether those findings translate to humans, and at what exposure level, is unknown. Extrapolating from a 28-day primate study to chronic human use is not scientifically defensible.

Risks from unregulated sources

The D(KLAKLAK)₂ domain in adipotide disrupts mitochondrial membranes in any cell that internalizes it in sufficient quantity. The compound's safety in the primate model depended on the targeting selectivity of the CKGGRAKDC homing peptide. Unregulated products may have the wrong sequence, incorrect folding, or contaminants that alter biodistribution. A compound that fails to home specifically to adipose vasculature but retains the proapoptotic effector domain presents a different toxicity profile than what was studied preclinically. Purity verification and source integrity are not available for compounds sold outside regulated pharmaceutical channels.

Who Should Not Use Adipotide

Based on the compound's proposed mechanisms and the preclinical safety data available, the following groups face elevated theoretical risk:

• Anyone with pre-existing kidney disease or reduced renal function, given the renal tubular toxicity signal observed in primate studies at weight-loss-relevant doses
• Individuals with active or suspected cancer, given that the vascular-ablation mechanism and prohibitin targeting have not been characterized in humans with tumor vasculature that may express prohibitin
• Pregnant or breastfeeding individuals, for whom no safety data of any kind exists
• Competitive athletes, as adipotide would fall under the WADA Prohibited List category S0 (non-approved substances) and its use carries disqualification risk independent of health considerations
• Anyone who has not established a current renal function baseline, given that kidney-function changes are the primary characterized safety concern in preclinical models

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

Understanding baseline biology is a reasonable step for anyone interested in metabolic research compounds. For adipotide specifically, the proposed mechanism and the identified safety signal both point to specific, measurable markers worth tracking.

• Creatinine and BUN (blood urea nitrogen): These are the primary serum markers of renal tubular function. Given that dose-dependent renal tubular changes were the principal safety finding in the Barnhart 2011 primate study, creatinine provides the most direct available proxy for monitoring renal status. Baseline values are necessary to interpret any subsequent change.
• Fasting insulin: The Kim 2012 Diabetes paper reported weight-independent glucose tolerance improvement in adipotide-treated mice, suggesting that adipose vascular disruption may have independent effects on insulin dynamics. A fasting insulin measurement establishes the baseline insulin-secretory and insulin-resistance picture that any weight-related intervention would alter.
• Fasting glucose and HbA1c: The primate study reported improved insulin resistance alongside weight loss. Fasting glucose captures acute glycemic status, while HbA1c provides a three-month average that reflects sustained glycemic patterns. Both are part of the metabolic picture that mechanistically connects adipose tissue, vascular function, and insulin sensitivity.
• High-sensitivity CRP (hs-CRP): Adipose tissue is a source of pro-inflammatory cytokines, and obesity-associated adipose expansion is associated with elevated systemic inflammation. Tracking hs-CRP provides a window into the inflammatory backdrop that vascular-targeting research compounds are studied against, and establishes whether baseline inflammation is a confounding variable.
• Fasting triglycerides: Fat tissue mass and lipolysis dynamics directly affect serum triglyceride levels. Triglycerides capture one of the most proximate biochemical correlates of adipose tissue turnover and provide context for metabolic research involving fat-loss compounds.
• A comprehensive metabolic panel: Because adipotide's safety concern is renal and the compound is metabolically active, a baseline metabolic panel — including liver enzymes, electrolytes, and kidney function markers — provides the full safety foundation that any investigation of this compound class would require.

For a curated view of which biomarkers are most informative in the context of metabolic health and weight loss, Superpower's best-biomarkers guide offers additional context organized around clinical utility.

When to Take This Seriously

If the biological question driving interest in adipotide is unwanted body fat, insulin resistance, or metabolic dysfunction, those are real and measurable problems with well-characterized clinical pathways. Endocrinologists, primary care physicians, and obesity medicine specialists evaluate the same underlying biology using markers that are well understood, FDA-approved pharmacological options supported by large-scale human trials, and lifestyle interventions with substantial clinical evidence. Establishing where your metabolic markers currently stand — fasting insulin, glucose, HbA1c, and inflammatory markers — gives any clinical conversation a concrete foundation. Objective data precedes good decisions.

That principle, measuring first and building from evidence, reflects Superpower's approach to preventive health: that understanding your biology is the precondition for every health decision worth making, whether you are evaluating established therapies or following the scientific literature on compounds that have not yet reached human trials.

IMPORTANT SAFETY INFORMATION

Adipotide (FTPP) is not FDA-approved for any indication. Adipotide has no approved drug application, no compounding status under 503A or 503B, and no legal pathway for human use in the United States. Superpower Health does not prescribe, sell, compound, or facilitate access to adipotide. This article is provided for educational and informational purposes only.

Safety profile in humans is unknown. The only available safety data comes from a 28-day rhesus macaque study by Barnhart and colleagues published in Science Translational Medicine in 2011 that identified dose-dependent, reversible renal tubular changes as the primary toxicity signal. No human pharmacokinetic data, no human maximum tolerated dose, and no human organ-specific toxicity profile have been published.

Do not use if: you have pre-existing kidney disease or reduced renal function; you are pregnant or breastfeeding; you have active or suspected cancer; you are a competitive athlete subject to WADA anti-doping rules.

Warnings: renal tubular toxicity (preclinical signal); unknown human dose-response relationship; no manufacturing oversight for products sold outside regulated pharmaceutical channels; contamination and misdosing risks from unregulated sources.

As of April 2026, no completed human efficacy or safety trials for adipotide have been published. Research interest does not constitute evidence of human safety or efficacy.

As of the 2026 WADA Prohibited List, adipotide would fall under category S0 (non-approved substances) and is prohibited in competition and out-of-competition for all sports.

Additional Questions

How is adipotide different from semaglutide or tirzepatide?

Adipotide and GLP-1 receptor agonists such as semaglutide and tirzepatide operate through entirely different mechanisms. GLP-1 receptor agonists modulate appetite and insulin secretion through hormonal signaling pathways that have been characterized in large-scale human trials. Adipotide targets the structural vasculature of white adipose tissue directly. It has not completed human trials. This comparison is offered for scientific context only; the compounds have fundamentally different regulatory statuses and evidence bases.

What biomarkers are relevant if I am researching adipotide?

Creatinine is the most directly relevant marker given the renal tubular toxicity signal in primate research. Fasting insulin, fasting glucose, and HbA1c capture the metabolic picture that adipotide's proposed mechanism would theoretically affect. Hs-CRP reflects the inflammatory context in which adipose vascular biology operates. A comprehensive metabolic panel establishing baseline kidney and liver function provides the full safety foundation for anyone following this area of research. The metabolic health biomarker testing library offers additional context on interpreting these values together.

Can a doctor prescribe adipotide?

No. Adipotide is not FDA-approved and is not on the list of compoundable bulk drug substances under 503A or 503B. No licensed provider can legally prescribe it in the United States. Any product currently available through online vendors is sold as "research use only," which means it is not intended for human use and is not subject to pharmaceutical-grade manufacturing standards.